Evaluation of Dutch guideline for just‐in‐time addition of plerixafor to stem cell mobilization in patients who fail with granulocyte–colony‐stimulating factor

Y. Bilgin,O. Visser,E. Beckers,Liane CJ Boome,C. Huisman,P. Ypma,A. Croockewit,T. Netelenbos,Ellen PA Kramer,G. Greef
DOI: https://doi.org/10.1111/trf.12979
2015-05-01
Transfusion
Abstract:Plerixafor in combination with granulocyte‐colony‐stimulating factor (G‐CSF) is approved for the use of stem cell collection in patients who fail to mobilize on G‐CSF. In 2009 the Stem Cell Working Party of the Dutch‐Belgian Cooperative Trial group for Hematology Oncology (HOVON) composed a guideline for the use of plerixafor. According to this guideline it is recommended to add plerixafor to G‐CSF in patients with circulating CD34+ cell counts of fewer than 20 × 106/L on 2 consecutive days accompanied by increasing white blood cells.
What problem does this paper attempt to address?